<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732574</url>
  </required_header>
  <id_info>
    <org_study_id>OPEP-2016</org_study_id>
    <nct_id>NCT02732574</nct_id>
  </id_info>
  <brief_title>Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery</brief_title>
  <official_title>The Effectiveness of Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery Surgery: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory dysfunction following cardiac surgery is well documented and due in part to the
      location of the incision and nature of the surgery. Post-operative pulmonary complications
      (PPCs) remain a significant problem following cardiac surgery, sometimes causing prolonged
      length of stay in hospital as well as increased morbidity and mortality; with the greater
      risk to older adults and individuals with obstructive lung disease. Positive expiratory
      pressure (PEP) therapy is thought to increase lung volumes and facilitate secretion
      clearance. The purpose of this study is to investigate whether the addition of oscillating
      PEP therapy to standard postoperative treatment is more effective in decreasing the incidence
      of PPCs and increasing functional capacity at time of discharge in 'high risk' patients
      undergoing elective cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory dysfunction following cardiac surgery is well documented and due in part to the
      location of the incision and nature of the surgery (Weissman, 2000; Garcia-Delgado M, et al.,
      2014). Patients undergoing cardiac surgery are at an increased risk of postoperative
      pulmonary complications including hypoxemia, atelectasis, and pneumonia (Weissman, 2000;
      Garcia-Delgado M, et al., 2014; O'Donohue WJ, 1992); with an increased risk in older
      individuals and individuals with obstructive lung disease (Crowe &amp; Bradley, 1997; Weissman
      2000; Jensen et al., 2007). Standard postoperative care includes early mobility and deep
      breathing and coughing (DB&amp;C) (Stiller K, et al., 1995; Johnson D., et al., 1996) usually
      initiated within the first 24 hours following surgery. Although standard care is sufficient
      in some instances, postoperative pulmonary complications (PPCs) remain a significant problem
      following cardiac surgery and can cause prolonged length of stay in the hospital and an
      increase in morbidity and mortality (Weissman, 2000; Garcia-Delgado M, et al., 2014) in a
      significant number of patients. Positive expiratory pressure (PEP) therapy is thought to
      increase lung volumes and facilitate secretion clearance in many populations (Orman J &amp;
      Wasterdahl E, 2009) and has been shown to be particularly effective in individuals with
      obstructive lung disease (Bott et al ., 2009). In consideration of the well documented
      respiratory dysfunction observed following cardiac surgery, PEP therapy may serve as a
      promising treatment in facilitating recovery in older, 'higher risk' individuals following
      elective cardiac surgery. Thus, the purpose of this study is to investigate whether the
      addition of oscillating PEP therapy is more effective than standard treatment alone in
      improving functional status at time of discharge, as well as decreasing oxygen requirements
      and the incidence of postoperative pulmonary complications (e.g., pneumonia, atelectasis,
      pneumothorax, pleural effusions) in 'high risk' patients undergoing elective cardiac surgery.

      Participants will be recruited from London Health Sciences Centre in London Ontario. Patients
      deciding to proceed with elective cardiac surgery will be screened in the surgeon's office,
      pre-admission clinic or the 6-inpatient ward for eligibility to participate in the study and
      provided with a letter of information. Each patient will be required to provide written
      consent in order to participate in this study. The study will be approved by the Health
      Sciences Research Ethics Board at Western University. Patients who have consented to
      participation in the study will be seen by the research coordinator at the patient's
      pre-operative clinic appointment where the research coordinator will explain the purpose and
      nature of the study and obtain written informed consent. Also, at that time, patient
      demographic information will be collected, as well as baseline data of chest x-ray (CXR) and
      a six minute walk test (6MWT). Pre-operative 6MWTs will be performed on a standardized 30
      meter track in the basement of University Hospital and will comply with the American Thoracic
      Society Guidelines (2002). Patients enrolled in the study will be randomized to one of two
      groups on the day of their surgery; OPEP treatment or sham treatment group. On the day of
      surgery or post-operative day (POD) 1, the research coordinator will bring the device (OPEP
      or sham depending on randomization) to the patient's room. The sham devices have been
      manufactured to be externally identical to the OPEP devices allowing for patient blinding,
      however the sham devices do not contain the internal mechanisms provided expiratory pressure.
      All patients (sham or OPEP) will be seen by a physiotherapist on the day of extubation and
      receive instructions on how to properly use the device, in addition to receiving standard
      post-operative care. Patients will be instructed to set the resistance on the device to the
      highest setting and perform up to 15 breaths in the sitting position at least twice per
      waking hour. The resistance and number of repetitions may be decreased to adjust for patient
      tolerance as deemed appropriate by the treating physiotherapist. Compliance will be measured
      through a log book completed by the patient and/or their family. Patients will be reassessed
      by a physiotherapist on POD #2 and #3 to ensure proper technique and compliance with the
      device. All patients will continue to receive standard care each day as per the clinical
      pathway and may receive additional cardiorespiratory PT techniques as deemed necessary by the
      PT. Patients will be instructed to continue with OPEP treatments (sham or OPEP) as described
      until POD #5. Outcome assessment will be conducted by a blinded assessor. The outcomes and
      timing of outcome assessment is described in the outcome measures section and will terminate
      on POD #7 or discharge from hospital, whichever occurs first. If patients require continuous
      positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or reintubation
      during this period, they will be instructed to stop using their OPEP device and outcome
      assessment will occur only until POD#7.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walk Test (6MWT) Distance (meters)</measure>
    <time_frame>Postoperative day 5</time_frame>
    <description>A 6MWT will be conducted as per American Thoracic Society guidelines in a designated hallway in the basement of university hospital or a corridor outside the cardiac surgery recovery unit. The tests will be conducted by a blinded assessor pre-operatively and on Postoperative day 5 or day of discharge, whichever comes first. Distance walked in meters will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total duration of oxygen therapy</measure>
    <time_frame>Time of tracheal extubation to Postoperative day 7</time_frame>
    <description>Cumulative duration of oxygen therapy will be tracked and recorded for all patients, tracked from time of extubation until Postoperative day 7 or discharge, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total exposure to oxygen therapy</measure>
    <time_frame>From tracheal extubation until Postoperative day 7</time_frame>
    <description>The cumulative exposure to oxygen post-extubation will be tracked by calculating an area under the dose-time curve for oxygen usage, tracked from time of extubation until Postoperative day 7 or discharge, whichever comes first..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cycles between room air and oxygen supplementation</measure>
    <time_frame>From tracheal extubation until Postoperative day 7</time_frame>
    <description>Each time someone goes from room air to back on oxygen, this is a setback, and we will count this one 'cycle', tracked from time of extubation until Postoperative day 7 or discharge, whichever comes first..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative pulmonary complications (PPCs) as determined by CXR interpretation</measure>
    <time_frame>Postoperative days 1 and 4</time_frame>
    <description>Incidence of PPCs will be assessed by a blinded assessor. PPCs will include:
pneumonia/consolidation
atelectasis
pleural effusions
pulmonary edema
pneumothorax.
Presence of each PPC will be expressed as a 3 point score: 0= absent, 1=mild (not likely clinically relevant), 2 = moderate to severe (likely clinically relevant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit (ICU) length of stay (LOS)</measure>
    <time_frame>Through study completion</time_frame>
    <description>time from admission to ICU (time 0) until actual discharge from ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital LOS</measure>
    <time_frame>Through study completion</time_frame>
    <description>Time from admission to ICU until actual discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause 30-day mortality</measure>
    <time_frame>Up to and including the 30th post-operative day</time_frame>
    <description>This will be determined by hospital records, a phone call to family physician (if available) or by phone call to patient or substitute decision maker.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of sham or OPEP device uses</measure>
    <time_frame>Days 1 through 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CPAP usage</measure>
    <time_frame>Up to postoperative day 7</time_frame>
    <description>Any patient who post-extubation requires CPAP therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>BiPAP usage</measure>
    <time_frame>Up to postoperative day 7</time_frame>
    <description>Any patient who post-extubation requires BiPAP therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Re-intubation</measure>
    <time_frame>Up to postoperative day 7</time_frame>
    <description>Any patient who post-extubation requires re-intubation of the trachea.</description>
  </other_outcome>
  <other_outcome>
    <measure>Borg shortness of breath scale</measure>
    <time_frame>Through study completion</time_frame>
    <description>During the postoperative six-minute walk test (on postoperative day 5 or discharge date, whichever comes first)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fatigue scale while performing six minute walk test</measure>
    <time_frame>Through study completion</time_frame>
    <description>The patient will assess their overall level of fatigue during the 6-min walk test on numeric rating scale (0 - not at all fatigued, 10 - maximally fatigued). During postoperative six minute walk test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Coronary Artery Bypass Grafting</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Older Adults</condition>
  <condition>Postoperative Pulmonary Complications</condition>
  <arm_group>
    <arm_group_label>OPEP Device Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM Device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oscilatory Positive Expiratory Pressure (OPEP) device</intervention_name>
    <description>OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.</description>
    <arm_group_label>OPEP Device Treatment</arm_group_label>
    <other_name>Aerobika</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SHAM Device Group</intervention_name>
    <description>SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.</description>
    <arm_group_label>SHAM Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Undergoing elective or urgent coronary artery bypass grafting (CABG) surgery at London
        Health Sciences Centre and satisfying the following criteria:

        Inclusion Criteria:

          -  CABG surgery or CABG-one valve (mitral or aortic) surgery (including conventional
             sternotomy on cardiopulmonary bypass, minimally-invasive and off-pump surgery)

          -  Age &gt;= 60 years

          -  Documentation of at least one of the following: (pre-operative fraction of expired
             volume in one second (FEV1) of less than 70% predicted), (pre-operative FEV1/forced
             vital capacity (FVC) of less than 80%), or (on any daily usage of inhaled
             anti-cholinergic, beta2-agonist, or corticosteroid)

          -  New York Heart Association (NYHA) â‰¥ 2

        Exclusion criteria:

          -  Patients not meeting inclusion for high risk surgical candidate

          -  Unable/unwilling to provide written informed consent

          -  Patients undergoing emergent cardiac surgery

          -  Untreated postoperative pneumothorax

          -  Patients on home CPAP or BiPAP therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip M Jones, MD, MSc (Clinical Trials)</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Fox, BA, RRT</last_name>
    <phone>519-685-8500</phone>
    <email>stephanie.fox@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Fox, BA, RRT</last_name>
      <phone>519-685-8500</phone>
      <email>stephanie.fox@lhsc.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Philip Jones</investigator_full_name>
    <investigator_title>Associate Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

